Shai Mulinari
21 – 40 of 91
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
“Black race”, “Schwarze Hautfarbe”, “Origine africaine”, or “Etnia nera”? The absent presence of race in European pharmaceutical regulation
2022) In BioSocieties(
- Contribution to journal › Article
-
Mark
Tip of the iceberg? Country- and company-level analysis of drug company payments for research and development in Europe
(
- Contribution to journal › Article
- 2021
-
Mark
Failure of responsive regulation? : Pharmaceutical marketing, corporate impression management and off-label promotion of enzalutamide in Europe
(
- Contribution to journal › Article
-
Mark
Pharmaceutical industry self-regulation and non-transparency : country and company level analysis of payments to healthcare professionals in seven European countries
(
- Contribution to journal › Article
-
Mark
Sweden
2021)(
- Chapter in Book/Report/Conference proceeding › Chapter in report
-
Mark
Data Transparency and Pharmaceutical Regulation in Europe : Road to Damascus, or Room without a View?
2021) p.63-94(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: A European policy review
(
- Contribution to journal › Article
-
Mark
Drug company payments to General Practices in England: cross-sectional and social network analysis
(
- Contribution to journal › Article
-
Mark
Is there evidence for the racialization of pharmaceutical regulation? : Systematic comparison of new drugs approved over five years in the USA and the EU
(
- Contribution to journal › Article
-
Mark
Sociologisk forskning om covid-19-pandemin : En introduktion
(
- Contribution to journal › Debate/Note/Editorial
- 2020
-
Mark
The will of Congress? Permissive regulation and the strategic use of labeling for the anti-influenza drug Relenza
(
- Contribution to journal › Article
-
Mark
Revisiting the pharmaceuticalisation of pandemic influenza using Lukes’ framework of power
(
- Contribution to journal › Article
-
Mark
Pharmaceutical lobbying and pandemic stockpiling : A feeling of déjà vu in the Nordic countries and why the sociological perspective is crucial to understand COVID-19
(
- Contribution to journal › Article
-
Mark
Sociologiska perspektiv på coronakrisen : Fyra sociologer om samhällets reaktion på covid-19
(
- Contribution to journal › Letter
-
Mark
Ras och genetiska skillnader : Introduktion till avsnittets texter
(
- Contribution to specialist publication or newspaper › Specialist publication article
-
Mark
Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012-2016)
(
- Contribution to journal › Article
-
Mark
Bengt Olle Bengtsson intervjuad av Shai Mulinari : Om genetisk likhet och skillnad
(
- Contribution to specialist publication or newspaper › Specialist publication article
-
Mark
Ras i genetikens tidevarv
(
- Contribution to specialist publication or newspaper › Specialist publication article
-
Mark
Svenska gener? : Om stratifierad precisionsmedicin och genetikens etniska gränsdragningar
(
- Contribution to specialist publication or newspaper › Specialist publication article
-
Mark
Five years of pharmaceutical industry funding of patient organisations in Sweden: cross-sectional study of companies, patient organisations and drugs
2020) In PLoS ONE(
- Contribution to journal › Article